|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2400 N Street, NW |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1945-12
|
||||||||
|
6. House ID# 305320000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lisa Hix |
Date | 4/20/2020 2:43:59 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; medical liability reform; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; the South Asian Heart Health Awareness and Research Act (HR 3131), research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; Senate price transparency workgroup; reduction/oversight of prior authorization and other administrative burdens (HR 3107); shared decision-making; medical isotope production and supply; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; surprise medical bills/balance billing, including HR 3630, the No Surprises Act; COVID-19 and the coronavirus, including HR 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act, HR 6201, the Families First Coronavirus Response Act and HR 748, the Coronavirus Aid, Relief, and Economic Security Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Natl Institutes of Health (NIH), White House Office, Agency for Healthcare Research & Quality (AHRQ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
Christine |
Perez |
|
|
|
Natalie |
Torentinos |
|
|
|
Kristine |
Rufener |
|
|
|
Joseph |
Cody |
|
|
|
Johnathon |
Kristan |
|
|
|
Claudia |
Vasquez |
|
|
|
James |
Vavricek |
|
|
|
Sarah |
Cartagena |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter aortic valve replacement, transcatheter mitral valve repair, myocardial positron emission tomography (PET) and hospital payment; access to Medicare claims data; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization, including HR 3107; the Stark Law and the in-office ancillary services exception, including the Medicare Care Coordination Improvement Act (HR 2282); Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation (HR 3911);graduate medical education policy including HR 1763/S 348, Resident Physician Shortage Reduction Act of 2019; end of life care; oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy, Medicaid coverage and eligibility, Medicare Part B Home Infusion Services Temporary Transitional Payment Act; Affordable Care Act repeal/replace/reform efforts; Ways and Means Committee Medicare extenders policy/legislation; paclitaxel mortality signal in PAD patients; cardiac CT payment; COVID-19 and the coronavirus, including HR 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act, HR 6201, the Families First Coronavirus Response Act and HR 748, the Coronavirus Aid, Relief, and Economic Security Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
James |
Vavricek |
|
|
|
Christine |
Perez |
|
|
|
Debra |
Mariani |
|
|
|
Natalie |
Torentinos |
|
|
|
Kristine |
Rufener |
|
|
|
Joseph |
Cody |
|
|
|
Johnathon |
Kristan |
|
|
|
Claudia |
Vasquez |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Tobacco use prevention and smoking cessation; FDA regulation of tobacco; Tobacco 21 legislation, electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations, including S.1258, S. 1541, S. 655, S. 1832, H.R. 2339, and H.R. 2339
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Nick |
Morse |
|
|
|
Lucas |
Sanders |
|
|
|
Natalie |
Torentinos |
|
|
|
Kristine |
Rufener |
|
|
|
Joseph |
Cody |
|
|
|
Johnathon |
Kristan |
|
|
|
James |
Vavricek |
|
|
|
Sarah |
Cartagena |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |